Lyell Immunopharma, Inc. Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent
Lyell Immunopharma, Inc. (LYEL) reported Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent of -$149.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Income Statement › Unrealized Gains
us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent · last filed 2026-08-06
- Lyell Immunopharma, Inc. other comprehensive income (loss), net of tax, portion attributable to parent for the quarter ending 2026-06-30 was -$149.00K.
- Lyell Immunopharma, Inc. other comprehensive income (loss), net of tax, portion attributable to parent for the quarter ending 2026-03-31 was -$251.00K.
- Lyell Immunopharma, Inc. other comprehensive income (loss), net of tax, portion attributable to parent for the quarter ending 2025-06-30 was -$101.00K.
- Lyell Immunopharma, Inc. other comprehensive income (loss), net of tax, portion attributable to parent for the quarter ending 2025-03-31 was -$133.00K.
| Period end | Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent 3 month | Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent 6 month |
|---|---|---|
| 2026-06-30 | -$149.00K 10-Q · filed 2026-08-06 | -$400.00K 10-Q · filed 2026-08-06 |
| 2026-03-31 | -$251.00K 10-Q · filed 2026-05-06 | |
| 2025-06-30 | -$101.00K 10-Q · filed 2026-08-06 | -$234.00K 10-Q · filed 2026-08-06 |
| 2025-03-31 | -$133.00K 10-Q · filed 2026-05-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Pyxis Oncology, Inc. (PYXS) | United States | $0.244B | |
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |
| Cue Biopharma, Inc. (CUE) | United States | $0.243B | -1.01 |
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| Akebia Therapeutics, Inc. (AKBA) | United States | $0.255B | -10.35 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |